George Golumbeski

Track

Insider profile

Currently holds positions in SAGE Therapeutics Inc, Enanta Pharmaceuticals Inc and MorphoSys AG

Performance

Overall performance
2.8
Performance over holding periods
2.8
30 days 90 days 120 days
Average return -0% 8.2% 15.1%
Success rate 56% 68% 82%
Transactions
4 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director SAGE Therapeutics Inc Jan. 23, 2019 -
Independent Director Enanta Pharmaceuticals Inc Feb. 7, 2014 -
Independent Member of the Supervisory Board MorphoSys AG May 17, 2018 -
Independent Director Acceleron Pharma Inc Jan. 1, 2011 - June 6, 2018
George Golumbeski's trades of SAGE Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
496.67
Quantity 52,724 -28.2%
Value US$1,020,090
Transaction date
Purchase
Price
14.81
Quantity 6,326 -10.3%
Value US$4,126,563
Transaction date
Purchase
Price
3.69
Quantity 26,049 +inf%
Value US$96,121
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2022-05-09 2022-05-05
B Purchase
50,316 +23.2%
304.65
US$4,561,656 		50,316 +23.2% 304.65 US$4,561,656
2022-04-27 2022-04-26
B Purchase
52,724 -28.2%
496.67
US$1,020,090 		52,724 -28.2% 496.67 US$1,020,090
2022-04-26 2022-04-22
B Purchase
6,326 -10.3%
14.81
US$4,126,563 		6,326 -10.3% 14.81 US$4,126,563
2022-04-26 2022-04-21
B Purchase
26,049 +inf%
3.69
US$96,121 		26,049 +inf% 3.69 US$96,121
2019-03-06 2019-03-04
PlS Planned sale
9,280 -100.0%
103.65
US$961,897 		9,280 -100.0% 103.65 US$961,897
2019-02-13 2019-02-12
PlS Planned sale
11,228 -100.0%
90.07
US$1,011,301 		11,228 -100.0% 90.07 US$1,011,301
2019-02-13 2019-02-11
PlS Planned sale
2,272 -100.0%
90.03
US$204,552 		2,272 -100.0% 90.03 US$204,552